Stockreport

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 f...

Arvinas, Inc.  (ARVN) 
Last arvinas, inc. earnings: 11/4 05:00 pm Check Earnings Report
PDF – Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas’ preclinical AR-V7 program, with the potential under the License A [Read more]